International Journal of Hematology

, Volume 76, Supplement 2, pp 123–131 | Cite as

Idiopathic thrombocytopenic purpura: Pathophysiology and management

  • Yeon S. Ahn
  • Lawrence L Horstman
Update on Bleeding Disorders

Abstract

Our understanding of the pathophysiology of ITP owes to pioneering work of W J Harrington in 1951, delineating the immunologic nature of platelet destruction. In ITP, antibody-coated platelets are destroyed by macrophages of RES. However, other mechanisms are also implicated: C-mediated platelet lysis and newly described C-independent peroxide injury. Both induce platelet fragmentation and lysis, generating procoagulant platelet microparticles (PMP). A third mechanism of platelet consumption in the microvasculature is proposed, based on overlapping syndromes of ITP and TTP in some patients. In assessing hemostasis in ITP, platelet counts alone is not sufficient. Evaluation of platelet clumping, giant platelets, and platelet activation, marked by increased PMP is useful. Patients with platelet activation or giant platelets bleed less and detection of clumping prevents unwarranted therapy. Thrombotic complications may develop in ITP. A syndrome, characterized by recurrent TIA-like symptoms, progressive memory loss due to ischemic small vessel disease is described. The management of ITP should include the search for and elimination of underlying causes and careful evaluation of hemostasis. Therapy is divided into definitive vs symptomatic measures. The former including splenectomy, danazol, chemotherapy offers lasting remission after therapy was stopped, while the later including glucocorticoids, gammaglobuin, antiD antibodies and others increases platelet counts but seldom sustains remission upon withdrawal. Danazol therapy is up-dated since it is an effective and safe definite measure in ITP.

Key Words

ITP Platelet microparticles Danazol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harrington WJ, Minnich V, Hollingsworth JW, et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.J Lab Clin Med. 1951;38:1–10.PubMedGoogle Scholar
  2. 2.
    Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura.Ann Int Med. 1953;38:433–469.PubMedGoogle Scholar
  3. 3.
    Harrington WJ, Minnich V, Arimura G. The autoimmune thrombocytopenias.Progress Hematol. 1956;1:166–192.Google Scholar
  4. 4.
    Shulman NR, Weinrach RS, Libre EP, et al. The role of reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura.Trans Assoc Am Physicans. 1965; 78:374–390.Google Scholar
  5. 5.
    Kosugi S, Kurata Y, Tomiyama Y. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura.Br J Haematol. 1996; 93:704–706.PubMedCrossRefGoogle Scholar
  6. 6.
    Aster RH, Keene WR. Sites of platelet destruction in idiopathic thrombocytopenic purpura.Br J Haematol. 1969;16:61–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Tsubakio T, Tani P, Curd JG, et al. Complement activation in vivo by antiplatelet antibodies in chronic immune thrombocytopenic purpura.Brit J Haematol. 1986;63:293–300.Google Scholar
  8. 8.
    Kiefel V, Salama A, Mueller-Eckhardt C. In vitro fixation of C3d and C5b-9 on platelets by human platelet reactive antibodies.Blut. 1989;58:33–37.PubMedCrossRefGoogle Scholar
  9. 9.
    Lehman HA, Lehman LO, Rustagi PK, et al. Complement mediated autoimmune thrombocytopenia.N Engl J Med. 1987; 316(4):194–198.PubMedCrossRefGoogle Scholar
  10. 10.
    Horstman LL, Jy W, Schultz DR, et al. Complement mediated fragmentation and lysis of opsonized platelets: Gender differences in sensitivity.J Lab Clin Med. 1994;123:515–525.PubMedGoogle Scholar
  11. 11.
    Wentworth P, Jones LH, Wentworth AD, et al. Antibody catalysis of the oxidation of water.Science. 2001;293:1806–1811.PubMedCrossRefGoogle Scholar
  12. 12.
    Nardi M, Tomlinson S, Greco MA, et al. Complement- independent, peroxide-induced antibody lyhsis of platelets in HIV-1-related immune thrombocytopenia.Cell. 2001;106:551–561.PubMedCrossRefGoogle Scholar
  13. 13.
    Olenich M, Schattner E. Postpartum thrombotic thrombocytopenic purpura (TTP) complicating pregnancy-associated immune thrombocytopenic purpura.Ann Int Med. 1994;120:845–847.PubMedGoogle Scholar
  14. 14.
    Stein RS, Flexner JM. Idiopathic thrombocytopenic purpura during remission of thrombotic thrombocytopenic purpura.Southern Med J. 1984;77:1599–1601.CrossRefPubMedGoogle Scholar
  15. 15.
    Krupsky M, Sarel R, Hurwitz N, et al. Late appearance of thrombotic thrombocytopenic purpura after autoimmune hemolytic anemia and in the course of chronic autoimmune thrombocytopenic purpura: two case reports.Acta Haematol. 1991; 85:139–142.PubMedCrossRefGoogle Scholar
  16. 16.
    Routy JP, Beaulieu R, Monte M, et al. Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV1 patients.Am J Hematol. 1991;38:328–328.CrossRefGoogle Scholar
  17. 17.
    Zucker-Franklin D, Karpatkin S. Red cell and platelet fragmentation in idiopathic thrombocytopenic purpura.N Engl J Med. 1977;297:517–523.PubMedGoogle Scholar
  18. 18.
    Clancy R, Jenkins E, Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopenic purpura.N Engl J Med. 1972;286:622–626.PubMedGoogle Scholar
  19. 19.
    Yanabu M, Suzuki M, Soga T, et al. Influence of antiplatelet autoantibodies on platelet function in immune thrombocytopenic purpura.Eur J Haematol. 1991;46:101–106.PubMedCrossRefGoogle Scholar
  20. 20.
    Balduini CL, Bertolino G, Noris P, et al. Defect of platelet aggregation and adhesion induced by autoantibodies against platelet glycoprotein IIIa.Thromb Haemost. 1992;68:208.PubMedGoogle Scholar
  21. 21.
    Varon D, Gitel SN, Varon N. Immune Bernard-Soulier-like syndrome associated with anti-glycoprotein-IX antibody.Am J Hematol. 1992;41:67.PubMedCrossRefGoogle Scholar
  22. 22.
    Pfueller SL, David R, Firkin BG, et al. Platelet aggregating IgG antibody to platelet surface glycoproteins associated with thrombosis and thrombocytopenia.Br J Haematol. 1990;74: 336–341.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen AM, Cycowitz Z, Mittelman M, et al. The incidence of pseudothrombocytopenia in automatic blood analyzers.Haematologia (Budap). 2000;30:117–121.CrossRefGoogle Scholar
  24. 24.
    Silvestri F, Virgolini L, Savignano C, et al. Incidence and diagnosis of EDTA-dependant pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombovytopenia.Vox Sang. 1995;68:35–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Schrezenmeier H, Muller H, Gunsilius E, et al. Anticoagulant-induced pseudothrombocytopenia and pseudoleucocytosis.Thromb Haemost. 1995;73:506–513.PubMedGoogle Scholar
  26. 26.
    Golanski J, Pietrucha T, Baj Z, et al. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal.Thromb Res. 1996;83:199–216.PubMedCrossRefGoogle Scholar
  27. 27.
    Lombarts AJ, Zijlstra JJ, Peters RH, et al. Accurate platelet counting in an insidious case of pseudothrombocytopenia.Clin Chem Lab Med. 1999;37:11–12.CrossRefGoogle Scholar
  28. 28.
    Sakurai S, Shiojima I, Tanigawa T, et al. Aminoglycosides prevent and dissociate the aggregation of platelets in patients with EDTA-dependent pseudothrombocytopenia.Br J Haematol. 1997; 99:817–823.PubMedCrossRefGoogle Scholar
  29. 29.
    Fiorin F, Steffan A, Pradella P, et al. IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb.Am J Clin Pathol. 1998;110:178–183.PubMedGoogle Scholar
  30. 30.
    vanVliet HH, Kappers-Klunne MC, Abels J. Pseudothrombocytopenia: a cold autoantibody against platelet glycoprotein GP IIb.Br J Haematol. 1986;62:501–511.CrossRefGoogle Scholar
  31. 31.
    Bizzaro N, Brandalise M. EDTA-dependent pseudothrombocytopenia: association with antiplatelet and antiphospholipid antibodies.Am J Clin Pathol. 1995;103:103–107.PubMedGoogle Scholar
  32. 32.
    Christopoulos CG, Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing fab fragments of chimaeric antibody.Br J Haematol. 1994; 87:650–652.PubMedCrossRefGoogle Scholar
  33. 33.
    Amorosi E, Garg SK, Karpatkin S. Heterogeneity of human platelets. IV. Identification of a young platelet population with selenomethionine.Br J Haematol. 1971;21:227.CrossRefGoogle Scholar
  34. 34.
    Garg SK, Amorosi EL, Karpatkin S. Use of the megathrombocyte as an index of megakaryocyte number.N Engl J Med. 1971;284:11.PubMedGoogle Scholar
  35. 35.
    Jy W, Horstman LL, Arce M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias.J Lab Clin Med. 1992;119:334–345.PubMedGoogle Scholar
  36. 36.
    Ahn YS, Cui Y, Horstman LL, et al. Chronic platelet activation and progressive vascular dementia in patients with immune thrombocytopenic purpura (ITP). In: Korczyn AD, editor. Proceedings: First International Congress on Vascular Dementia. Geneva, Switzerland: Monduzzi Editore; 1999. p.83–86.Google Scholar
  37. 37.
    Horstman LL, Ahn YS. Platelet microparticles: A wide-angle perspective.Crit Rev Oncol/Hematol. 1999;30:111–142.CrossRefGoogle Scholar
  38. 38.
    Ahn YS, Jy W, Jimenez JJ, et al. Vascular dementia among patients with ITP (immune thrombocytopenic purpura) and risk factors.Blood. 2000;96(11,Prt1; Presented at 42nd ASH Meeting):250a.Google Scholar
  39. 39.
    Miyamoto S, Marcinkiewicz C, EdmundsJr LH, et al. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GP IIb/IIIa.Thromb Haemost. 1998;80:225–230.PubMedGoogle Scholar
  40. 40.
    Ozner MD, Ahn YS, Horstman LL, et al. Chronic platelet activation and acute coronary syndromes in 13 middle-aged patients.Clin Appl Thromb Hemost. 1997;3:46–53.Google Scholar
  41. 41.
    Ahn YS, Horstman LL, Jy W, et al. Thrombotic complications in patients with ITP [abstract].Thromb Haemost. 2001;July Suppl (Presented at XVIII Congress of ISTH):Google Scholar
  42. 42.
    Ahn YS, Harrington WJ, Mylvaganam R. Immunosuppressant therapy of idiopathic thrombocytopenic purpura ITP.Spring Semin Immunopathol. 1984;7:35–42.CrossRefGoogle Scholar
  43. 43.
    George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments].Blood. 1996;92:1556–1564.Google Scholar
  44. 44.
    Cines DB, Blanchette VS, Chir B. Immune Thrombocytopenic purpura.N Engl J Med. 2002;346:995–1008.PubMedCrossRefGoogle Scholar
  45. 45.
    Emilia G, Longo G, Luppi M. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura.Blood. 2001;97:812–814.PubMedCrossRefGoogle Scholar
  46. 46.
    Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura.Br J Haematol. 2001;115:1002–1003.PubMedCrossRefGoogle Scholar
  47. 47.
    Robinette CD, FraumeniJr JF. Splenectomy and subsequent mortality in veterans of the 1936–1945 war.Lancet (Jul 16). 1977;2:127–129.Google Scholar
  48. 48.
    Ahn YS, Harrington WJ, Simon SR, et al. Danazol for the treatment of idiopathic thrombocytopenic purpura.N Engl J Med. 1983;308:1396–1399.PubMedCrossRefGoogle Scholar
  49. 49.
    Ahn YS, Mylvaganam R, Garcia RO, et al. Low-dose danazol for ITP.Ann Int Med. 1987;107:177–181.PubMedGoogle Scholar
  50. 50.
    Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women.Annals Int Med. 1989;111:723–728.Google Scholar
  51. 51.
    Ahn YS. Danazol for hematologic disorders.Acta Hematol. 1990;84:122–129.CrossRefGoogle Scholar
  52. 52.
    Ansar SA, Penhale W, Talal N. Sex hormones, immune responses and auto- immune diseases. Mechanisms of sex hormone action.Am J Path. 1983;121:531.Google Scholar
  53. 53.
    Ahn YS, Harrington WJ, Seelman RC, et al. Vincristine therapy of idiopathic and secondary thrombocytopenias.N Engl J Med. 1974;291:376–380.PubMedCrossRefGoogle Scholar
  54. 54.
    Ahn YS, Byrnes JJ, Harrington WJ, et al. The treatment of idiopathic thrombocytopenia with vincristine-loaded platelets.N Engl J Med. 1978;298:1101.PubMedCrossRefGoogle Scholar
  55. 55.
    Ahn YS, Harrington WJ, Mylvaganam R, et al. Slow infusion of vinca alkaloid in the treatment of ITP.Ann Int Med. 1984;100:192–196.PubMedGoogle Scholar
  56. 56.
    Ahn YS, Mylvaganam R, Harrington WJ. Use of platelets as drug carriers for the treatment of hematologic diseases.Meth Enzymol. 1987;149:312–326.PubMedCrossRefGoogle Scholar
  57. 57.
    Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.Blood. 2001;98: 952–957.PubMedCrossRefGoogle Scholar
  58. 58.
    Madanes AE, Farber M. Danazol.Ann Int Med. 1982;96:625–630.PubMedGoogle Scholar
  59. 59.
    McVerry BA, Auger M, Bellingham AJ. The use of danazol in the management of chronic immune thrombocytopenic purpura.Br J Haematol. 1985;61:145–148.PubMedCrossRefGoogle Scholar
  60. 60.
    Almagro D. Danazol in idiopathic thrombocytopenic purpura [letter].Acta Haematol. 1985;74:120.PubMedCrossRefGoogle Scholar
  61. 61.
    Buelli M, Corelazzo S, Viero P, et al. Danazol for the treatment of idiopathic thrombocytopenic purpura.Acta Haematol. 1985; 74:97–98.PubMedCrossRefGoogle Scholar
  62. 62.
    Heyd J, Hershko C. Use of danazol in the management of chronic idiopathic thrombocytopenic purpura.Isr J Med Sci. 1985;21:418–420.PubMedGoogle Scholar
  63. 63.
    Marwahn RK, Singh RP, EtAl. Danazol therapy in immune thrombocytopenic purpura.Pediatr Hematol Oncol. 1990;7:193–198.CrossRefGoogle Scholar
  64. 64.
    Weinblatt ME, Kochen J, Ortega J. Danazol for children with immune thrombocytopenic purpura.Am J Dis Child. 1988; 142:1317–1319.PubMedGoogle Scholar
  65. 65.
    West SG, Johnson SC. Danazol for treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus.Ann Int Med. 1988;108:703–706.PubMedGoogle Scholar
  66. 66.
    Manoharan A. Danazol therapy in patients with immune cytopenias.Aust NZ J Med. 1987;17:613–614.Google Scholar
  67. 67.
    Mazzucconi MG, Francesconi M, Falcione E, et al. Danazol therapy in refractory chronic immune thrombocytopenic purpura.Acta Hematol. 1987;77:45–47.CrossRefGoogle Scholar
  68. 68.
    Kotlarek-Haus S, Podolak-Dawidziak M. Danazol in chronic idiopathic thrombocytopenic purpura resistent to corticosteroids.Folia Haematol Int Mag Klin Morphol Blutforsch. 1987;114:768–776.PubMedGoogle Scholar
  69. 69.
    Fenaux P, Quiquandon I, Huart J, et al. The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases.Nouv Rev Fr Hematol. 1990; 32:143–146.PubMedGoogle Scholar
  70. 70.
    Nalli G, EtAl. Danazol therapy for idiopathic thrombocytopenic purpura (ITP).Haematologica. 1988;73:55–57.PubMedGoogle Scholar
  71. 71.
    Ambriz R, Puzzuto J, Morales M, et al. Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP).Nouv Rev Fr Hematol. 1986;28: 275–279.PubMedGoogle Scholar
  72. 72.
    Ambriz-Fernandez R, GChavez-Sanchez, Pizzuto-Chavez J, et al. Danazol In refractory autoimmune thrombocytopenic purpura (ATP) a new therapeutic sequence.Arch Invest Med. 1985;16:295.Google Scholar
  73. 73.
    Schreiber AD, Chien P, Tomaski A, et al. Effect of danazol in immune thrombocytopenic purpura.N Engl J Med. 1987; 316:503–508.PubMedCrossRefGoogle Scholar
  74. 74.
    Kondo H, Iseki T, Goto S, et al. Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy.Int J Hematol. 1992;55:293–300.PubMedGoogle Scholar
  75. 75.
    Blanco R, EtAl. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases.Br J Rheumatol. 1997;36:1095–1099.PubMedCrossRefGoogle Scholar
  76. 76.
    Saulsbury FT, Bringelsen KA. Danazol therapy for chronic immune-mediated thrombocytopenic purpura in a patient with common variable immunodeficiency.Am J Pediatr Hematol Oncol. 1991;13:326–329.PubMedCrossRefGoogle Scholar
  77. 77.
    Choudhry VP, Kashyap R, Ahlawat S, et al. Vinblastine and danazol therapy in steroid resistent childhood chronic idiopathic thrombocytopenic purpura.Int J Hematol. 1995;61: 157–162.PubMedCrossRefGoogle Scholar
  78. 78.
    Schiavotto C, Castaman G, Rodeghiero F. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contrainidcation for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol.Haematologica. 1993;78(suppl 2):29–34.PubMedGoogle Scholar
  79. 79.
    Richards KM, Ferraris VA. Mitral valve replacement in a patient with idiopathic thrombocytopenic purpura: preoperative treatment with danazol.J Cardiovasc Surg (Torino). 1991; 32:840–842.Google Scholar
  80. 80.
    Edelman DZ, Knobel B, Virag I, et al. Danazol in non-splenectomized patients with refractory thrombocytopenic purpura.Postgrad Med J. 1990;66:827–830.CrossRefGoogle Scholar
  81. 81.
    Horstman LL, Jy W, Arce M, et al. Danazol distribution in plasma and cell membranes as related to altered cell properties: Implications for mechanism.Am J Hematol. 1995;50:179–187.PubMedCrossRefGoogle Scholar
  82. 82.
    Potts GO, Schane HP, Edelson J. Pharmacology and pharmacokinetics of danazol.Drugs. 1980;19:321–330.PubMedCrossRefGoogle Scholar
  83. 83.
    Fujisawa K, Tani P, Piro L, et al. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura.Blood. 1993;81:2872–2877.PubMedGoogle Scholar
  84. 84.
    Mylvaganam R, Ahn YS, Harrington WJ, et al. Immune modulation by danazol in autoimmune thrombocytopenia.Clin Immunol Immunopath. 1987;42:281–287.CrossRefGoogle Scholar
  85. 85.
    Ahn YS, Fernandez LF, Kim CI, et al. Danazol therapy renders red cells resistant to osmotic lysis.FASEB J. 1989; 3:157–162.PubMedGoogle Scholar
  86. 86.
    Horstman LL, Jy W, Ahn YS. Danazol inhibits autoantibody binding to erythrocytes in vitro at physiologic concentrations.Clin Res. 1991;39:364A.Google Scholar
  87. 87.
    Hosea SW, Santaella ML, Brown EJ, et al. Long-term therapy of hereditary angioedema with danazol.Ann Int Med. 1980; 93:809–812.PubMedGoogle Scholar
  88. 88.
    Nesher G, Dollberg L, Zimran A, et al. Hepatosplenic peliosis after danazol and glucocorticoids for ITP [letter].N Engl J Med. 1985;312:242.PubMedGoogle Scholar
  89. 89.
    Buamah P. An apparent Danazol induced primary hepatocellular carcinoma Đ Case report.J Surg Oncol. 1985;28:114.PubMedCrossRefGoogle Scholar
  90. 90.
    Ahn YS, Harrington WJ, Mylvaganam R, et al. Danazol therapy for autoimmune hemolytic anemia.Ann Int Med. 1985;102:298–301.PubMedGoogle Scholar
  91. 91.
    Harrington(Sr) WJ, Kolodny L, Horstman LL, et al. Danazol for paroxysmal nocturnal hemoglobinuria.Amer J Hemat. 1997;54:149–154.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Yeon S. Ahn
    • 1
  • Lawrence L Horstman
    • 1
  1. 1.Dept. of Medicine, Division of Hematology/OncologyUniversity of MiamiUSA

Personalised recommendations